Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker…
The bill directs HHS to develop a rulemaking plan to impose most-favored-nation price targets so U.S. drug prices are comparable to similarly developed countries.
It requires HHS certification and waiver guidance for individual importation from developed low-cost countries, asks DOJ and the FTC to enforce anticompetitive conduct by manufacturers, directs HHS to facilitate direct-to-consumer purchasing at the determined prices, and orders Commerce and USTR to study manufacturer practices affecting national security and price suppression.
A report to Congress is required within 180 days on the study findings.
Ambitious federal price controls, vague implementation details, and expected strong industry and legal challenges make enactment unlikely absent major amendment.
Relative to its intended legislative type, this bill establishes a clear policy objective and assigns roles to several federal actors, but it remains high-level and under-specified for a major regulatory intervention. It includes limited deadlines and a directed study, but omits detailed methodologies, enforcement mechanisms, fiscal considerations, and comprehensive implementation sequencing.
Lib-left emphasizes immediate price relief and fairness to patients.
Lib-left emphasizes immediate price relief and fairness to patients.
Likely broadly favorable: the bill directly targets high U.S. drug prices through international benchmarking, importation, antitrust enforcement, and facilitating lower-cost direct sales.
Supports aggressive federal action to reduce patient costs and address perceived U.S. subsidization of global R&D, while wanting strong safety and access safeguards.
Cautiously supportive of goals but concerned about implementation, legal risk, and unintended effects.
Views international benchmarking and antitrust enforcement as reasonable tools if enacted carefully, with technical safeguards and periodic review to limit market disruption.
Generally skeptical: views the bill as federal overreach that effectively imposes price controls and invites legal conflict.
Concerned it will harm innovation incentives, expand regulatory power, and create safety or supply problems through importation and price mandates.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Ambitious federal price controls, vague implementation details, and expected strong industry and legal challenges make enactment unlikely absent major amendment.
The bill has not accumulated any surfaced votes yet.
Lib-left emphasizes immediate price relief and fairness to patients.
Ambitious federal price controls, vague implementation details, and expected strong industry and legal challenges make enactment unlikely a…
Relative to its intended legislative type, this bill establishes a clear policy objective and assigns roles to several federal actors, but it remains high-level and under-specified for a major regulatory intervention. I…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.